Six-Month Follow-Up
Prescribing declined from discharge to six months for ACEi/ARB/ARNI, beta-blockers, and MRAs. SGLT2 inhibitor use increased after discharge, suggesting delayed initiation. Among patients discharged on quadruple therapy, about 90% received…
1 sources - 5 claims
Prescribing declined from discharge to six months for ACEi/ARB/ARNI, beta-blockers, and MRAs. SGLT2 inhibitor use increased after discharge, suggesting delayed initiation. Among patients discharged on quadruple therapy, about 90% received ACEi/ARB/ARNI and beta-blockers at no more than half of guideline target dose. SGLT2 inhibitors generally did not require titration and were usually prescribed near guideline target dose. Six-month follow-up data were available for 2026 patients, or 50.7% of the cohort.